Sign inJoin waitlistJoin the waitlist

Pierre Triozzi

Professor Emeritus · Wake Forest University Baptist Medical Center

Credentials: · · · · ·

History

Wake Forest University Baptist Medical Center
Present

Hematology and Medical Oncology
Duke University Hospital
1983–1986
Internal Medicine
Duke University Hospital
1980–1983
Ohio State University College of Medicine
1976–1980

Research

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest…
Journal of Clinical Oncology · 1992 · 608 citations
Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
OncoImmunology · 2018 · 236 citations
Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study
Annals of Surgical Oncology · 2020 · 142 citations

Arun Singh
23 papers
JR
John Rinehart
15 papers
Julian Kim
15 papers · 4 as a resident
Yogen Saunthararajah
11 papers
EB
Ernest Borden
9 papers
Jimmy Ruiz
8 papers
RT
Raymond Tubbs
8 papers
EM
Edward Martin
7 papers
Michael Chan
7 papers
Brian Rini
6 papers
Jorge Garcia
6 papers · 2 as a fellow
RC
Robert Conry
6 papers

Grants

Differentiation Therapy of Uveal Melanoma Micrometastases
National Cancer Institute · R21
Contact PI · $379.1K · Wake Forest University Health Sciences
2013–2016
AAV-Based Plasmacytoid Dendritic Cell Cancer Vaccine
National Cancer Institute · R01
Contact PI · $1.1M · Cleveland Clinic Lerner Com-Cwru
2006–2012
Uveal Melanoma Micrometastasis
National Cancer Institute · R01
Contact PI · $651.6K · Cleveland Clinic Lerner Com-Cwru
2009–2011
Intratumoral Dendritic Cells Plus Interleukin-2
National Cancer Institute · R21
Contact PI · $381.2K · University of Alabama at Birmingham
2001–2004

Clinical trials

APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery
Principal investigator · Completed · Phase 1
Wake Forest University Health Sciences
2017–2020
APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
Principal investigator · Completed · Phase 1
Wake Forest University Health Sciences
2014–2016
A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer
Principal investigator · Unknown · Phase 1
Vascular Biogenics Ltd. operating as VBL Therapeutics
2007–2015
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2021–2027